Quarterly report [Sections 13 or 15(d)]

Segment Information (Tables)

v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Financial Information

The following table summarizes the segment’s financial information including the Company’s significant segment expenses:

    2025     2024  
   

Quarters Ended

March 31,

 
    2025     2024  
Research and development   $          
Clinical     726,321       870,915  
Nonclinical     144,701       120,403  
Personnel related     410,119       609,423  
Total research and development   $ 1,281,141     $ 1,600,741  
General and administrative     1,058,662       1,602,819  
Interest income     36,216       69,298  
Net loss   $ (2,303,587 )     (3,134,262 )